Citations

Mayo Clinic

Clear

52 citation(s) found for "I, Anu R".

Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India
Mathew, Aju , Davis, Sissmol , Boby, Jeffrey Mathew , I, Anu R , Suryavanshi, Moushumi , Dawood, Shaheenah , Panda, Pankaj Kumar , Nag, Shona, Das, Arunangshu, Rohatgi, Nitesh, Shah, Riyaz , Thampy, Cherian, Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar, Popat, Sanjay , Parikh, Aparna Raj , Yadav, Siddhartha , Mehta, Prashant , Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar , Sirohi, Bhawna , Dawood, Shaheenah , Popat, Sanjay , Parikh, Aparna R. , Yadav, Siddhartha , Singh, Randeep K. , Sirohi, Bhawna

JCO Global Oncology | March 14, 2024 | Volume: No volume available | Issue: 10 | Pages: No page available

10.1200/go.23.00330 | PMID 38484196 Get It

PURPOSE Accurate understanding of the genomic and transcriptomic data provided by next-generation sequencing (NGS) is essential for the effective utilization of precision oncology. Molecular tumor boards (MTBs) aim to translate the complex data in NGS reports into effective clinical interventions. Often, MTB treatment recommendations differ from those in the NGS reports. In this study, we analyze the discordance between these recommendations and the rationales behind the discordances, in a non–high-income setting, with international input to evaluate the necessity of MTB in clinical practice. METHODS We collated data from MTB that were virtually hosted in Chennai, India. We included patients with malignancies who had NGS reports on solid tissue or liquid biopsies, and excluded those with incomplete data. MTB forms and NGS reports of each clinical case were analyzed and evaluated for recommendation concordance. Concordance was defined as an agreement between the first recommendation in the MTB forms and the therapeutic recommendations suggested in the NGS report. Discordance was the absence of the said agreement. The rationales for discordance were identified and documented. RESULTS Seventy MTB reports were analyzed with 49 cases meeting the inclusion criteria. The recommendation discordance was 49% (24 of 49). Discordant recommendations were mainly due to low level of evidence for the drug (75% of cases). CONCLUSION The discordance between MTB and NGS vendor recommendations highlights the clinical utility of MTB. The educational experiences provided by this initiative are an example of how virtual academic collaborations can enhance patient care and provider education across geographic borders.
Hormonal Exposures Relate to Clinical Phenotype in Women with Neuromyelitis Optica (S12.005)
Bove, Riley , Elsone, Liene, Borisow, Nadja, Sorum, Jaime, Mutch, Kerry , Tobyne, Sean , Ruprecht, Klemens , Buckle, Guy J., Wingerchuk, Dean M. , Friedemann, Paul, Weinshenker, Brian, Jacob, Anu , Klawiter, Eric C. , Álvarez, Enrique , Cortez, Melissa , Mateen, Farrah J. , Mealy, Maureen A. , Levy, Michael , Friedemann, Paul, Cross, Anne H. , Chitnis, Tanuja

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s12.005 Get It

High Risk of Initial Symptom Onset Post-Partum in Neuromyelitis Optica (S60.001)
Klawiter, Eric C. , Elsone, Liene, Borisow, Nadja, Bove, Riley , Sorum, Jaime, Mutch, Kerry , Tobyne, Sean , Musallam, Alexander, Ruprecht, Klemens , Buckle, Guy, Levy, Michael, Jacob, Anu, Álvarez, Enrique , Mateen, Farrah J. , Buckle, Guy, Paul, Friedemann , Levy, Michael, Cross, Anne H. , Jacob, Anu, Chitnis, Tanuja , Weinshenker, Brian G.

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.s60.001 Get It

New Acute Severity Scale for Neuromyelitis Optica Relapses (P5.249)
Jarius, Sven , Aktaş, Orhan , Broadley, Simon , Cabre, Philippe, Han, May , Jacob, Anu , John, Gareth, Leite, Maria Isabel , Marignier, Romain , Schippling, Sven , Weinshenker, Brian, Wingerchuk, Dean M. , Levy, Michael , Mealy, Maureen A. , Paul, Friedemann , Nakashima, Ichiro , Palace, Jacqueline , Traboulsee, Anthony

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p5.249 Get It

Urinary Proteomics for Discovery of Gastric Cancer Biomarkers to Enable Precision Clinical Oncology
Joshi, Neha , Bhat, Firdous Ahmad , Bellad, Anikha , Jain, Anu, Sirdeshmukh, Ravi, Pandey, Akhilesh , Bhat, Firdous, Chavan, Sandip , Pandey, Akhilesh , Bellad, Anikha , Joshi, Neha S , Sathe, Gajanan

OMICS: A Journal of Integrative Biology | August 14, 2023 | Volume: 27 | Issue: 8 | Pages: 361-371

10.1089/omi.2023.0077 | PMID 37579183 Get It

For precision in clinical oncology practice, detection of tumor-derived peptides and proteins in urine offers an attractive and noninvasive alternative for diagnostic or screening purposes. In this study, we report comparative quantitative proteomic profiling of urine samples from patients with gastric cancer and healthy controls using tandem mass tags-based multiplexed mass spectrometry approach. We identified 1504 proteins, of which 246 were differentially expressed in gastric cancer cases. Notably, ephrin A1 (EFNA1), pepsinogen A3 (PGA3), sortilin 1 (SORT1), and vitronectin (VTN) were among the upregulated proteins, which are known to play crucial roles in the progression of gastric cancer. We also found other overexpressed proteins, including shisa family member 5 (SHISA5), mucin like 1 (MUCL1), and leukocyte cell derived chemotaxin 2 (LECT2), which had not previously been linked to gastric cancer. Using a novel approach for targeted proteomics, SureQuant, we validated changes in abundance of a subset of proteins discovered in this study. We confirmed the overexpression of vitronectin and sortilin 1 in an independent set of urine samples. Altogether, this study provides molecular candidates for biomarker development in gastric cancer, and the findings also support the promise of urinary proteomics for noninvasive diagnostics and personalized/precision medicine in the oncology clinic.
Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India.
Davis, Sissmol , I, Anu R , Suryavanshi, Moushumi , Dawood, Shaheenah , Panda, Pankaj Kumar , Nag, Shona, Das, Arunangshu, Rohatgi, Nitesh, Shah, Riyaz , Thampy, Cherian, Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar, Mathew, Aju , Sirohi, Bhawna , Dawood, Shaheenah , Popat, Sanjay , Parikh, Aparna R. , Yadav, Siddhartha , Mehta, Prashant , Singh, Randeep K.

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e15050-e15050

10.1200/jco.2023.41.16_suppl.e15050 Get It

e15050 Background: Molecular tumour boards (MTB) facilitate discussions among medical professionals, scientists, bioinformaticians and geneticists for clinical application of precision oncology, via interpretation of various genomic sequencing studies, most commonly Next Generation Sequencing (NGS). NGS test vendor recommendation may differ from the MTB recommendations. We aim to study the discordance rate between these recommendations. Methods: MTB discussions between April 1, 2021 and December 31, 2021, were retrospectively evaluated. MTBs which assessed NGS reports with or without significant genetic mutations but with drug recommendations were included. NGS testing was done with multiple vendors. Patients from all over India, Nepal, Bangladesh, Dubai and Abu Dhabi were discussed. We excluded MTBs which assessed NGS data without any drug recommendations. We compared therapeutic recommendations provided in the NGS report with the first-choice recommendation in the MTB discussion. Recommendation discordance was defined as disagreement between the NGS recommendation and the first MTB recommendation that either instructed its implementation either immediately or on disease progression. Results: 70 MTB data was studied. 49 MTBs assessing NGS reports of 49 unique patients (median age 54 years; range, 32-82) were included in the study. 13 patients had lung cancer, 10 colorectal, 6 breast, 7 hepatopancreatobiliary, 4 carcinoma of unknown primary and 9 others. 17 did not provide any treatment recommendations and hence were excluded. 4 were discussions based on NGS reports previously discussed in an MTB that was already included in the study, hence were excluded. Recommendation discordance rate was 49% (24 of 49). Conclusions: To our knowledge, this is the first study that assessed discordance rate in recommendations between NGS report and MTB from a low- and middle-income country setting. Accurate clinical translation of complex genomic data is at the forefront of personalized cancer care.
Recommendations for developing effective and safe paediatric and congenital heart disease services in low-income and middle-income countries: a public health framework
Hasan, Babar , Bhatti, Areesh, Mohsin, Shazia , Ahmed, Eltayeb Mohamed , Ali, Sulafa , Amanullah, Muneer , Ansong, Annette , Banu, Tahmina , Bolman, R. Morton , Borim, Bruna Cury , Callus, Edward , Caputo, Massimo , Hernández, Tomás Chalela, Croti, Ulisses Alexandre , Ejigu, Yayehyirad , Fenton, Kathleen N. , Gomanju, Anu , Harahsheh, Ashraf S. , Hesslein, Peter S., Hugo‐Hamman, Christopher , Kpodonu, Jacques , Malik, Mahim, Nichani, Sanjiv, Overman, David M. , Quenot, Alexis Palacios-Macedo, Bolman, Ceeya Patton, Pearson, Dorothy, Raju, Vijayakumar , Ross, Shelagh, Sandoval, Néstor , Shidhika, Fenny, Sivalingam, Sivakumar , Verstappen, Amy, Vervoort, Dominique , Zühlke, Liesl , Harahsheh, Ashraf S , Overman, David, Vervoort, Dominique , Zheleva, Bistra , Bhatti, Areesh, Barach, Paul Randall , Beaton, Andrea , Breinholt, John P. , Cardarelli, Marcelo G. , Khan, Sohail Hassan , Kumar, Raman , Jenkins, Kathy J. , Lakhoo, Kokila , Novick, William M. , Quenot, Alexis Palacios Macedo, Ross, Shelagh, Sholler, Gary F. , Sharma, Rajesh , Zheleva, Bistra

BMJ Global Health | May 4, 2023 | Volume: 8 | Issue: 5 | Pages: e012049

10.1136/bmjgh-2023-012049 | PMID 37142298 Get It

The global burden of paediatric and congenital heart disease (PCHD) is substantial. We propose a novel public health framework with recommendations for developing effective and safe PCHD services in low-income and middle-income countries (LMICs). This framework was created by the Global Initiative for Children’s Surgery Cardiac Surgery working group in collaboration with a group of international rexperts in providing paediatric and congenital cardiac care to patients with CHD and rheumatic heart disease (RHD) in LMICs. Effective and safe PCHD care is inaccessible to many, and there is no consensus on the best approaches to provide meaningful access in resource-limited settings, where it is often needed the most. Considering the high inequity in access to care for CHD and RHD, we aimed to create an actionable framework for health practitioners, policy makers and patients that supports treatment and prevention. It was formulated based on rigorous evaluation of available guidelines and standards of care and builds on a consensus process about the competencies needed at each step of the care continuum. We recommend a tier-based framework for PCHD care integrated within existing health systems. Each level of care is expected to meet minimum benchmarks and ensure high-quality and family centred care. We propose that cardiac surgery capabilities should only be developed at the more advanced levels on hospitals that have an established foundation of cardiology and cardiac surgery services, including screening, diagnostics, inpatient and outpatient care, postoperative care and cardiac catheterisation. This approach requires a quality control system and close collaboration between the different levels of care to facilitate the journey and care of every child with heart disease. This effort was designed to guide readers and leaders in taking action, strengthening capacity, evaluating impact, advancing policy and engaging in partnerships to guide facilities providing PCHD care in LMICs.
Spaceflight alters insulin and estrogen signaling pathways
Tabetah, Marshall , Karim, Rashid , Zaksas, Victoria , I, Anu, Muratani, Masafumi , Tasoula, Alexia , Singh, Ruth Subhash, Chen, Yen-Kai, Povero, Davide , Klotz, Rémi , Mason, Christopher E. , Clair, Riley St, Karouia, Fathi , Mathyk, Begüm Aydoğan , Kim, JangKeun , Chen, Yen-Kai, Overbey, Eliah G. , Park, Jiwoon , Borg, Joseph , Yu, Min A , Young, Steven L. , Mason, Christopher E , Szewczyk, Nathaniel J. , Clair, Riley M. St. , Beheshti, Afshin

No container title available | January 4, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2362750/v1 Get It

Abstract Organismal adaptations to spaceflight have been characterized at the molecular level in model organisms, including Drosophila and C. elegans. Here we extend molecular work to energy metabolism and sex hormone signaling in mice and humans. We found spaceflight-induced changes in insulin and estrogen signaling in rodents and humans. Murine changes were most prominent in the liver, where we observed inhibition of insulin and estrogen receptor signaling with concomitant hepatic insulin resistance and steatosis. Based on the metabolic demand, metabolic pathways mediated by insulin and estrogen vary among muscles, specifically between the soleus and extensor digitorum longus. In humans, spaceflight induced changes in insulin and estrogen related genes and pathways. Pathway analysis demonstrated spaceflight-induced changes in insulin resistance, estrogen signaling, stress response, and viral infection. These data strongly suggest the need for further research on the metabolic and reproductive endocrinologic effects of space travel, if we are to become a successful interplanetary species